Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT® (amivantamab-vmjw)

A study by Johnson & Johnson revealed a pre-medication regimen with dexamethasone significantly reduced infusion-related reactions with RYBREVANT for NSCLC patients, showing a three-fold decrease in reaction rates compared to standard management.